MENTOR
Membranous Nephropathy Trial of Rituximab
Paciente / Población Intervención / Exposición Comparación Desenlace
In 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.
N
130
Diseño
Open-label RCT
Desenlace
Complete or partial remission of proteinuria at month 24
Relevancia
2
ResultadoRituximab 60% vs cyclosporine 20% at 24mo (risk difference 40pp, 95% CI 25-55, P<0.001 superiority); noninferior at 12mo (60% vs 52%, P=0.004).
Fervenza FC, et al. N Engl J Med. 2019;381(1):36-46. 10.1056/NEJMoa1814427
Discusión y crítica
Established rituximab as a first-line option in KDIGO 2021; deeper and earlier anti-PLA2R decline than with cyclosporine.